$BIOLQ
BIOLASE, INC Stock $biolq

$biolq Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-K Financial Statement

#000119312513110112 Filed on March 15, 2013

Income Statement

Concept	2012 Q4	2012	2011 Q4
Revenue	$19.08M	$57.36M	$13.16M
YoY Change	44.98%	17.39%	35.39%
Cost Of Revenue	$10.19M	$30.88M	$7.610M
YoY Change	33.9%	12.12%	55.62%
Gross Profit	$8.890M	$26.48M	$5.550M
YoY Change	60.18%	24.2%	14.91%
Gross Profit Margin	46.59%	46.16%	42.17%
Selling, General & Admin	$6.670M	$24.33M	$6.420M
YoY Change	3.89%	15.77%	76.37%
% of Gross Profit	75.03%	91.87%	115.68%
Research & Development	$1.030M	$4.684M	$1.070M
YoY Change	-3.74%	8.65%	33.75%
% of Gross Profit	11.59%	17.69%	19.28%
Depreciation & Amortization	$140.0K	$513.0K	$140.0K
YoY Change	0.0%	-26.19%	-41.67%
% of Gross Profit	1.57%	1.94%	2.52%
Operating Expenses	$7.700M	$29.01M	$7.490M
YoY Change	2.8%	14.56%	69.07%
Operating Profit	$1.190M	-$2.531M	-$1.940M
YoY Change	-161.34%	-36.79%	-585.0%
Interest Expense	-$140.0K	$239.0K	-$80.00K
YoY Change	75.0%	-21.64%	-55.56%
% of Operating Profit	-11.76%
Other Income/Expense, Net		-$414.0K
YoY Change		5.34%
Pretax Income	$1.060M	-$2.945M	-$2.020M
YoY Change	-152.48%	-33.02%	-1222.22%
Income Tax	$10.00K	$111.0K	$10.00K
% Of Pretax Income	0.94%
Net Earnings	$1.040M	-$3.056M	-$2.030M
YoY Change	-151.23%	-31.88%	-1294.12%
Net Earnings / Revenue	5.45%	-5.33%	-15.43%
Basic Earnings Per Share		-$0.10
Diluted Earnings Per Share	$149.2K	-$0.10	-$317.2K
COMMON SHARES
Basic Shares Outstanding	31.12M shares	32.16M
Diluted Shares Outstanding		32.16M

Balance Sheet

Concept	2012 Q4	2012	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.540M	$2.540M	$3.310M
YoY Change	-23.26%	-23.26%	95.86%
Cash & Equivalents	$2.543M	$2.540M	$3.307M
Short-Term Investments
Other Short-Term Assets	$1.550M	$1.550M	$1.810M
YoY Change	-14.36%	-14.36%	33.09%
Inventory	$11.14M	$11.14M	$11.31M
Prepaid Expenses
Receivables	$11.68M	$11.46M	$8.899M
Other Receivables	$179.0K	$220.0K	$287.0K
Total Short-Term Assets	$26.92M	$26.92M	$25.33M
YoY Change	6.28%	6.28%	89.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.509M	$1.510M	$1.148M
YoY Change	31.45%	31.3%	-13.68%
Goodwill	$2.926M		$2.926M
YoY Change	0.0%
Intangibles	$300.0K		$212.0K
YoY Change	41.51%
Long-Term Investments
YoY Change
Other Assets	$305.0K	$320.0K	$187.0K
YoY Change	63.1%	60.0%	3.89%
Total Long-Term Assets	$5.056M	$5.050M	$4.481M
YoY Change	12.83%	12.72%	-6.26%
TOTAL ASSETS
Total Short-Term Assets	$26.92M	$26.92M	$25.33M
Total Long-Term Assets	$5.056M	$5.050M	$4.481M
Total Assets	$31.97M	$31.97M	$29.81M
YoY Change	7.27%	7.25%	64.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.663M	$7.660M	$7.804M
YoY Change	-1.81%	-1.79%	93.65%
Accrued Expenses	$6.267M	$5.280M	$6.177M
YoY Change	1.46%	-14.56%	12.72%
Deferred Revenue
YoY Change
Short-Term Debt	$1.640M	$1.640M	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.38M	$19.38M	$16.28M
YoY Change	19.0%	19.04%	-17.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$138.0K	$140.0K	$337.0K
YoY Change	-59.05%	-61.11%	-65.96%
Total Long-Term Liabilities	$138.0K	$140.0K	$337.0K
YoY Change	-59.05%	-61.11%	-65.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.38M	$19.38M	$16.28M
Total Long-Term Liabilities	$138.0K	$140.0K	$337.0K
Total Liabilities	$20.18M	$20.18M	$17.24M
YoY Change	17.06%	17.05%	-18.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$112.3M		-$109.2M
YoY Change	2.8%
Common Stock	$34.00K		$138.5M
YoY Change	-99.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$16.40M		$16.40M
YoY Change	0.0%
Treasury Stock Shares	$1.964M		$1.964M
Shareholders Equity	$11.79M	$11.79M	$12.57M
YoY Change
Total Liabilities & Shareholders Equity	$31.97M	$31.97M	$29.81M
YoY Change	7.27%	7.25%	64.23%

Cashflow Statement

Concept	2012 Q4	2012	2011 Q4
OPERATING ACTIVITIES
Net Income	$1.040M	-$3.056M	-$2.030M
YoY Change	-151.23%	-31.88%	-1294.12%
Depreciation, Depletion And Amortization	$140.0K	$513.0K	$140.0K
YoY Change	0.0%	-26.19%	-41.67%
Cash From Operating Activities	$1.900M	-$1.664M	-$2.020M
YoY Change	-194.06%	-87.51%	741.67%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	$808.0K	-$140.0K
YoY Change	-35.71%	88.79%	600.0%
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	$110.0K	$0.00
YoY Change
Cash From Investing Activities	-$110.0K	-$698.0K	-$140.0K
YoY Change	-21.43%	63.08%	600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$235.0K
YoY Change		-101.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-550.0K	1.559M	-240.0K
YoY Change	129.17%	-89.87%	-4.0%
NET CHANGE
Cash From Operating Activities	1.900M	-1.664M	-2.020M
Cash From Investing Activities	-110.0K	-698.0K	-140.0K
Cash From Financing Activities	-550.0K	1.559M	-240.0K
Net Change In Cash	1.900M	-803.0K	-2.400M
YoY Change	-179.17%	-148.99%	370.59%
FREE CASH FLOW
Cash From Operating Activities	$1.900M	-$1.664M	-$2.020M
Capital Expenditures	-$90.00K	$808.0K	-$140.0K
Free Cash Flow	$1.990M	-$2.472M	-$1.880M
YoY Change	-205.85%	-82.02%	754.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2006Q1	biol	Lease Facility Area LeaseFacilityArea	57000	sqft
CY2012Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	8000000
CY2012Q2	biol	Fair Value Of Warrants FairValueOfWarrants	135000
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31343661	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	57615816
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	7929000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.5
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2975000
CY2009Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2235000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3650000	shares
CY2010Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2301000
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-3047000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.60
CY2010Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	424000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1694000
CY2010Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2725000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4130000	shares
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1808000
CY2011Q4	us-gaap	Goodwill Goodwill	2926000
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8312000
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	145000
CY2011Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	433000
CY2011Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	2218000
CY2011Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2218000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33784000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-586000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	11794000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	300000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	12569000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	212000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	187000
CY2011Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2600000
CY2011Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	731000
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1928000
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1964000	shares
CY2011Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	41000
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30538000	shares
CY2011Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	144000
CY2011Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	669000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1959000
CY2011Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2538000
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	399000
CY2011Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	287000
CY2011Q4	us-gaap	Liabilities Liabilities	17238000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7804000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1066000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26075000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2136000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	337000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2011Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	526000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1322000
CY2011Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8000
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109212000
CY2011Q4	us-gaap	Assets Assets	29807000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.75
CY2011Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2300000
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	594000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	2450000
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8899000
CY2011Q4	us-gaap	Inventory Net InventoryNet	11312000
CY2011Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	1056000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29807000
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16399000
CY2011Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	165000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3307000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2576000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32502000	shares
CY2011Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2218000
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	212000
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-360000
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6177000
CY2011Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4280000
CY2011Q4	us-gaap	Goodwill Gross GoodwillGross	2926000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16282000
CY2011Q4	us-gaap	Deferred Revenue DeferredRevenue	2161000
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	289000
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7164000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1148000
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4494000
CY2011Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	357000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3858000	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	33000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	25000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2364000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	25326000
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33929000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	906000
CY2011Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	576000
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138507000
CY2011Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	101000
CY2011Q4	biol	Deferred Tax Assets Unrealized Currency Exchange Gain DeferredTaxAssetsUnrealizedCurrencyExchangeGain	99000
CY2011Q4	biol	Deferred Tax Liabilities State Taxes DeferredTaxLiabilitiesStateTaxes
CY2011Q4	biol	Royalties Receivables RoyaltiesReceivables	29000
CY2011Q4	biol	Trade Account Receivable TradeAccountReceivable	8583000
CY2011Q4	biol	Financed Insurance Premium Finance Charge FinancedInsurancePremiumFinanceCharge	0.025	pure
CY2011Q4	biol	Accrued Support Services AccruedSupportServices	200000
CY2011Q4	biol	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment
CY2011Q4	biol	Undelivered Elements Training Installation And Product And Support Services UndeliveredElementsTrainingInstallationAndProductAndSupportServices	1105000
CY2011Q4	biol	Stockholders Equity Excluding Treasury Stock StockholdersEquityExcludingTreasuryStock	28968000
CY2011Q4	biol	Financed Insurance Premium Payable FinancedInsurancePremiumPayable	433000
CY2011Q4	biol	Undelivered Elements Extended Warranty Current UndeliveredElementsExtendedWarrantyCurrent	1056000
CY2011Q4	biol	Undelivered Elements Extended Warranty Noncurrent UndeliveredElementsExtendedWarrantyNoncurrent	25000
CY2011Q4	biol	Deferred Tax Assets Excluded From Valuation Allowance DeferredTaxAssetsExcludedFromValuationAllowance	8000
CY2011Q4	biol	Deferred Tax Liabilities Capitalized Intangible Assets DeferredTaxLiabilitiesCapitalizedIntangibleAssets	630000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1552000
CY2012Q4	us-gaap	Goodwill Goodwill	2926000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	683000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8027000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	175000
CY2012Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1637000
CY2012Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	751000
CY2012Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	1699000
CY2012Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1699000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33341000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-647000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	305000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	62000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2314000	shares
CY2012Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	19000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1900000
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	822000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	226000
CY2012Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.48
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	195000
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	328000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2012Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3860000	shares
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2326000
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1964000	shares
CY2012Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2314000	shares
CY2012Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	45000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.02
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	199000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31284000	shares
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	91000
CY2012Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	9700000
CY2012Q4	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	1600000
CY2012Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	127000
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	502000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	192000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2348000
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1949000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	618000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	414000
CY2012Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	179000
CY2012Q4	us-gaap	Liabilities Liabilities	20179000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7663000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1226000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25746000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	118000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3226000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	138000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2012Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	763000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1167000
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	16000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112268000
CY2012Q4	us-gaap	Assets Assets	31973000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.48
CY2012Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	8000000
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1900000
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	663000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	2082000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11680000
CY2012Q4	us-gaap	Inventory Net InventoryNet	11142000
CY2012Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	1506000
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31973000
CY2012Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	29000
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16399000
CY2012Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	6400000
CY2012Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	582000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2543000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2800000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33248000	shares
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	42800000
CY2012Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1699000
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	300000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-320000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6267000
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	18000
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4017000
CY2012Q4	us-gaap	Goodwill Gross GoodwillGross	2926000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	51000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	69000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19375000
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	3229000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	304000
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5176000
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	240000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3860000	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	34000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2500000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	26917000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	67000000
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33516000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	868000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1493000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6518000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1509000
CY2012Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	405000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140747000
CY2012Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	119000
CY2012Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.02
CY2012Q4	biol	Working Capital WorkingCapital	7500000
CY2012Q4	biol	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
CY2012Q4	biol	Deferred Tax Assets Unrealized Currency Exchange Gain DeferredTaxAssetsUnrealizedCurrencyExchangeGain	160000
CY2012Q4	biol	Deferred Tax Liabilities State Taxes DeferredTaxLiabilitiesStateTaxes
CY2012Q4	biol	Royalties Receivables RoyaltiesReceivables	45000
CY2012Q4	biol	Trade Account Receivable TradeAccountReceivable	11456000
CY2012Q4	biol	Financed Insurance Premium Finance Charge FinancedInsurancePremiumFinanceCharge	0.030	pure
CY2012Q4	biol	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment
CY2012Q4	biol	Undelivered Elements Training Installation And Product And Support Services UndeliveredElementsTrainingInstallationAndProductAndSupportServices	1723000
CY2012Q4	biol	Stockholders Equity Excluding Treasury Stock StockholdersEquityExcludingTreasuryStock	28193000
CY2012Q4	biol	Financed Insurance Premium Payable FinancedInsurancePremiumPayable	379000
CY2012Q4	biol	Undelivered Elements Extended Warranty Current UndeliveredElementsExtendedWarrantyCurrent	1506000
CY2012Q4	biol	Undelivered Elements Extended Warranty Noncurrent UndeliveredElementsExtendedWarrantyNoncurrent	3000
CY2012Q4	biol	Deferred Tax Assets Excluded From Valuation Allowance DeferredTaxAssetsExcludedFromValuationAllowance	16000
CY2012Q4	biol	Deferred Tax Liabilities Capitalized Intangible Assets DeferredTaxLiabilitiesCapitalizedIntangibleAssets	703000
CY2012Q4	biol	Unrecognized Tax Benefits Impact Additional Paid In Capital If Realized UnrecognizedTaxBenefitsImpactAdditionalPaidInCapitalIfRealized	1500000
CY2012Q4	biol	Change In Control Employee Severance ChangeInControlEmployeeSeverance	714000
CY2010Q3	biol	Ir Warrants Issued To Purchase Common Stock Price Per Share IrWarrantsIssuedToPurchaseCommonStockPricePerShare	0.74
CY2006Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	38692
CY2006Q1	biol	Lease Term LeaseTerm	P5Y
CY2009Q3	biol	Period For Extended Lease PeriodForExtendedLease	April 20, 2015
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0194	pure
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	111000
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-11495000
CY2010	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-87000
CY2010	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.064	pure
CY2010	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	115000
CY2010	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	300000
CY2010	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	3126000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.008	pure
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	727000
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12123000
CY2010	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-18000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.013	pure
CY2010	us-gaap	Asset Impairment Charges AssetImpairmentCharges	35000
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1070000
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	727000
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.91
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-773000
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	55000
CY2010	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-80000
CY2010	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	225000	shares
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.006	pure
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-19000
CY2010	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005	pure
CY2010	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	199000
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3812000
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-237000
CY2010	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000
CY2010	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	85000
CY2010	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	16000
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1016000
CY2010	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	5877000
CY2010	us-gaap	Product Warranty Expense ProductWarrantyExpense	2636000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.89
CY2010	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	70000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.069	pure
CY2010	us-gaap	Interest Expense Other InterestExpenseOther	5000
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	237000
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1281000
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6557000
CY2010	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3000000
CY2010	us-gaap	Advertising Expense AdvertisingExpense	610000
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-173000
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26250000	shares
CY2010	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	37000
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	199000
CY2010	us-gaap	Sales Revenue Net SalesRevenueNet	26225000
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-978000
CY2010	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-102000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11963000
CY2010	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9938000
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2010	us-gaap	Licenses Revenue LicensesRevenue	145000
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3790000
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2814000
CY2010	us-gaap	Cost Of Revenue CostOfRevenue	17400000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1386000	shares
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.001	pure
CY2010	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	35000
CY2010	us-gaap	Operating Expenses OperatingExpenses	20320000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.91	pure
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26250000	shares
CY2010	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-874000
CY2010	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	849000.0
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.304	pure
CY2010	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-3000
CY2010	us-gaap	Depreciation Depreciation	940000
CY2010	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-96000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.038	pure
CY2010	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-55000
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	727000
CY2010	us-gaap	Gross Profit GrossProfit	8825000
CY2010	us-gaap	Interest Paid InterestPaid	236000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.027	pure
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	76000
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4282000	shares
CY2010	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	5000
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-12021000
CY2010	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-468000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	87000
CY2010	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-110000
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000
CY2010	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-46000
CY2010	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	130000
CY2010	us-gaap	Interest Expense InterestExpense	361000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.09
CY2010	biol	Total Deferred Income Tax Expense Benefit TotalDeferredIncomeTaxExpenseBenefit	76000
CY2010	biol	Effective Income Tax Rate Reconciliation Other Reconciling Items EffectiveIncomeTaxRateReconciliationOtherReconcilingItems	-0.009	pure
CY2010	biol	Other Equity Instruments Compensation OtherEquityInstrumentsCompensation	19000
CY2010	biol	License Fees And Royalty Revenue LicenseFeesAndRoyaltyRevenue	1645000
CY2010	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend	0.00
CY2010	biol	No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue	No individual international country represented more than 10% of net revenue
CY2010	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOne	P4Y6M15D
CY2010	biol	Products And Services Revenue ProductsAndServicesRevenue	24580000
CY2010	biol	Share Based Compensation Net Impact On Earning Per Share Diluted ShareBasedCompensationNetImpactOnEarningPerShareDiluted	-0.03
CY2010	biol	Percentage Of Sales Concentration To One Customer PercentageOfSalesConcentrationToOneCustomer	0.38	pure
CY2010	biol	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue	713000
CY2010	biol	Adjustments To Additional Paid In Capital Non Employee Equity Instruments AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments	19000
CY2010	biol	Sales To Customers Located Within United States SalesToCustomersLocatedWithinUnitedStates	0.64	pure
CY2010	biol	Sales To Customers Located Outside Of United States SalesToCustomersLocatedOutsideOfUnitedStates	0.36	pure
CY2010	biol	Cost Of Revenue Prior To Nonrecurring Event CostOfRevenuePriorToNonrecurringEvent	17400000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0153	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1328000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-4004000
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-250000
CY2011	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.202	pure
CY2011	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2700000
CY2011	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1586000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.038	pure
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1528000
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4522000
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	36000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.023	pure
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	695000
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	1528000
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.92
CY2011	us-gaap	Sales Returns And Allowances Goods SalesReturnsAndAllowancesGoods	110000
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4230000
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	66000
CY2011	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	74000
CY2011	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	657000	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.030	pure
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	268000
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.022	pure
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1244000
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13320000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-428000
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-16000
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	79000
CY2011	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	-5711000
CY2011	us-gaap	Product Warranty Expense ProductWarrantyExpense	2093000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.08
CY2011	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	99000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.181	pure
CY2011	us-gaap	Interest Expense Other InterestExpenseOther	5000
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17223000
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	428000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1613000
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7936000
CY2011	us-gaap	Inventory Write Down InventoryWriteDown	392000
CY2011	us-gaap	Advertising Expense AdvertisingExpense	444000
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	552000
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29907000	shares
CY2011	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	78000
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1244000
CY2011	us-gaap	Sales Revenue Net SalesRevenueNet	48858000
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5642000
CY2011	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-36000
CY2011	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	18000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4397000
CY2011	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13075000
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2011	us-gaap	Licenses Revenue LicensesRevenue	64000
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4311000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15387000
CY2011	us-gaap	Cost Of Revenue CostOfRevenue	27540000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	766000	shares
CY2011	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	130000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002	pure
CY2011	us-gaap	Operating Expenses OperatingExpenses	25322000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.05	pure
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29907000	shares
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4716000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16000
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.023	pure
CY2011	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	20000
CY2011	us-gaap	Depreciation Depreciation	565000
CY2011	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	44000
CY2011	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-36000
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1528000
CY2011	us-gaap	Gross Profit GrossProfit	21318000
CY2011	us-gaap	Interest Paid InterestPaid	80000
CY2011	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	Less than 10%
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.020	pure
CY2011	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	273000
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	53000
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4626000	shares
CY2011	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-4486000
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-393000
CY2011	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	1165715	shares
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	250000
CY2011	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-88000
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	89000
CY2011	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-26000
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	130000
CY2011	us-gaap	Interest Expense InterestExpense	305000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.97
CY2011	biol	Total Deferred Income Tax Expense Benefit TotalDeferredIncomeTaxExpenseBenefit	53000
CY2011	biol	Effective Income Tax Rate Reconciliation Other Reconciling Items EffectiveIncomeTaxRateReconciliationOtherReconcilingItems	-0.001	pure
CY2011	biol	Proceeds From Sale Of Common Stock Net Of Issuance Costs ProceedsFromSaleOfCommonStockNetOfIssuanceCosts	17223000
CY2011	biol	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	18000
CY2011	biol	Adjustments To Additional Paid In Capital Warrant Repurchased AdjustmentsToAdditionalPaidInCapitalWarrantRepurchased	130000
CY2011	biol	Other Equity Instruments Compensation OtherEquityInstrumentsCompensation	273000
CY2011	biol	License Fees And Royalty Revenue LicenseFeesAndRoyaltyRevenue	439000
CY2011	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend	0.00
CY2011	biol	No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue	No individual international country represented more than 10% of net revenue
CY2011	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOne	P4Y1M24D
CY2011	biol	Products And Services Revenue ProductsAndServicesRevenue	48419000
CY2011	biol	Share Based Compensation Net Impact On Earning Per Share Diluted ShareBasedCompensationNetImpactOnEarningPerShareDiluted	-0.05
CY2011	biol	Payments Of Stock Repurchase Costs PaymentsOfStockRepurchaseCosts	268000
CY2011	biol	Percentage Of Sales Concentration To One Customer PercentageOfSalesConcentrationToOneCustomer	0.19	pure
CY2011	biol	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue	1259000
CY2011	biol	Adjustments To Additional Paid In Capital Non Employee Equity Instruments AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments	273000
CY2011	biol	Sales To Customers Located Within United States SalesToCustomersLocatedWithinUnitedStates	0.67	pure
CY2011	biol	Sales To Customers Located Outside Of United States SalesToCustomersLocatedOutsideOfUnitedStates	0.33	pure
CY2011	biol	Cost Of Revenue Prior To Nonrecurring Event CostOfRevenuePriorToNonrecurringEvent	27540000
CY2012	dei	Trading Symbol TradingSymbol	BIOL
CY2012	dei	Entity Registrant Name EntityRegistrantName	BIOLASE, INC
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0000811240
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0077	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	91000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-2531000
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-250000
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.282	pure
CY2012	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	142000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M10D
CY2012	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1705000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.061	pure
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1600000
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3016000
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	50000
CY2012	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	120000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.037	pure
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	513000
CY2012	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	16600000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1600000
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.63
CY2012	us-gaap	Sales Returns And Allowances Goods SalesReturnsAndAllowancesGoods	110000
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-347000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	57000
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	241000
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	214000	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	208000	shares
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Concentration of credit risk, interest rate risk and foreign currency exchange rate risk</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company invests its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers which allow management to monitor current changes in business operations respond as needed. The Company does not, generally, require customers to provide collateral before it sells them products; however is has required certain distributors to make prepayments for significant purchases of products. For the years ended December 31, 2012, 2011, and 2010, sales to Henry Schein, Inc. (“HSIC”) worldwide accounted for approximately 3%, 19%, and 38%, respectively, of our net sales.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, including the facilities, consulting services and employee-related costs. To date, the Company has not entered into any hedging contracts. Future fluctuations in the value of the U.S. dollar may, however, affect the price competitiveness of the Company’s products outside the United States.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Management’s primary objective in managing the Company’s cash balances has been preservation of principal and maintenance of liquidity to meet the Company’s operating needs. Most of the Company’s excess cash balances are invested in money market accounts in which there is minimal interest rate risk. An increase in the LIBOR rate associated with the Company’s lines of credit would increase the interest expense the Company must pay. The Company’s risk associated with fluctuation in interest expense is limited to its outstanding lines of credit balances. The Company does not use interest rate derivative instruments to manage exposure to interest rate changes.</font></p> </div>
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2012	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	235000
CY2012	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	200000
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.039	pure
CY2012	us-gaap	Short Term Debt Description ShortTermDebtDescription	Nine
CY2012	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	124000
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	455000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1664000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-698000
CY2012	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	304000
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	12000
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1068000
CY2012	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	417000
CY2012	us-gaap	Product Warranty Expense ProductWarrantyExpense	2224000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
CY2012	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	14963000
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	91000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041	pure
CY2012	us-gaap	Interest Expense Other InterestExpenseOther	5000
CY2012	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	808000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-764000
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8075000
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	330000
CY2012	us-gaap	Advertising Expense AdvertisingExpense	907000
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-450000
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y2M12D
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31308000	shares
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	455000
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	57356000
CY2012	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y11M16D
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3222000
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	40000
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2945000
CY2012	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16250000
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2012	us-gaap	Licenses Revenue LicensesRevenue	0
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4684000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1559000
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	30878000
CY2012	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	19000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	966000	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.006	pure
CY2012	us-gaap	Operating Expenses OperatingExpenses	29009000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.97	pure
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31308000	shares
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	160000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	18000
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	789000.0
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M16D
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.130	pure
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	32000
CY2012	us-gaap	Depreciation Depreciation	377000
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	62000
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-15000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1600000
CY2012	us-gaap	Gross Profit GrossProfit	26478000
CY2012	us-gaap	Operating Loss Carryforwards Expiration Dates OperatingLossCarryforwardsExpirationDates	2013
CY2012	us-gaap	Interest Paid InterestPaid	88000
CY2012	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	Less than 10%
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.162	pure
CY2012	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	23000
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14000
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	61000
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	43000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	160000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4713000	shares
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-8000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3056000
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-414000
CY2012	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	634162	shares
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	250000
CY2012	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-175000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	111000
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	39000
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory and deferred taxes, as well as estimates for accrued warranty expenses, indefinite-lived intangible assets and the ability of goodwill to be realized, revenue deferrals for multiple element arrangements, effects of stock-based compensation and warrants, contingent liabilities and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</font></p> </div>
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	136000
CY2012	us-gaap	Debt Issuance Costs DebtIssuanceCosts	91000
CY2012	us-gaap	Interest Expense InterestExpense	239000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.39
CY2012	biol	Total Deferred Income Tax Expense Benefit TotalDeferredIncomeTaxExpenseBenefit	61000
CY2012	biol	Effective Income Tax Rate Reconciliation Other Reconciling Items EffectiveIncomeTaxRateReconciliationOtherReconcilingItems	0.006	pure
CY2012	biol	Indefinite Lived Intangible Assets Useful Life IndefiniteLivedIntangibleAssetsUsefulLife	Indefinite life
CY2012	biol	Unrecognized Tax Benefits That Would Impact Additional Paid In Capital UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital	6400000
CY2012	biol	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	6000
CY2012	biol	Non Recurring Revenue NonRecurringRevenue	1141000
CY2012	biol	Other Equity Instruments Compensation OtherEquityInstrumentsCompensation	23000
CY2012	biol	Decreased Revenues Pursuant To Two Thousand And Twelve Termination Agreement DecreasedRevenuesPursuantToTwoThousandAndTwelveTerminationAgreement	1100000
CY2012	biol	License Fees And Royalty Revenue LicenseFeesAndRoyaltyRevenue	165000
CY2012	biol	Number Revolving Credit Facility Agreements NumberRevolvingCreditFacilityAgreements	2	Agreement
CY2012	biol	Derecognized Accrued Warranties Pursuant To Two Thousand And Twelve Termination Agreement DerecognizedAccruedWarrantiesPursuantToTwoThousandAndTwelveTerminationAgreement	142000
CY2012	biol	Non Recurring Cost Of Revenue NonRecurringCostOfRevenue	1141000
CY2012	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend	0.00
CY2012	biol	No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue	No individual international country represented more than 10% of net revenue
CY2012	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOne	P3Y8M12D
CY2012	biol	Products And Services Revenue ProductsAndServicesRevenue	58332000
CY2012	biol	Reversal Of Sales And Marketing Service Liabilities Pursuant To Two Thousand And Twelve Termination Agreement ReversalOfSalesAndMarketingServiceLiabilitiesPursuantToTwoThousandAndTwelveTerminationAgreement	350000
CY2012	biol	Agreed Upon Purchase Price Pursuant To Two Thousand And Twelve Termination Agreement AgreedUponPurchasePricePursuantToTwoThousandAndTwelveTerminationAgreement	1100000
CY2012	biol	Non Recurring Events NonRecurringEvents	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>NOTE 11 — NON-RECURRING EVENT</b></font></p> <!-- xbrl,body --> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">On April 12, 2012, the Company completed the 2012 Termination Agreement with HSIC whereby the Company purchased HSIC’s inventory of Waterlase MD Turbo laser systems for approximately $1.1 million and HSIC released its liens on the Company’s assets. Pursuant to the terms of the 2012 Termination Agreement, the Company paid the entire purchase price by offsetting accounts receivable currently due from HSIC from sales made in the normal course of business. None of the funds used to offset the purchase price were related to the original sales of the MD Turbo laser systems that were purchased. During the year ended December 31, 2012, the Company sold all laser systems purchased under this arrangement at margins consistent with the Company’s comparable laser products.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">As a result of the transaction, the Company recorded a decrease to accounts receivable of approximately $1.1 million with a corresponding decrease to revenue to pay for the purchase of the Waterlase MD Turbo laser systems. The Company also recorded an increase to inventory for the same amount with a corresponding decrease to cost of revenue to record the inventory acquired. As such, while the Company’s revenues and cost of revenues were both reduced by $1.1 million to record the effects of the transaction, there was no effect on the Company’s gross profit during the year ended December 31, 2012. Additionally, as a result of the transaction, during the year ended December 31, 2012, the Company de-recognized approximately $155,000 of accounts receivable due from HSIC related to support services previously provided to HSIC and approximately $142,000 of accrued warranties previously provided to HSIC and reversed accrued sales and marketing service liabilities of approximately $350,000.</font></p> </div>
CY2012	biol	Share Based Compensation Net Impact On Earning Per Share Diluted ShareBasedCompensationNetImpactOnEarningPerShareDiluted	-0.05
CY2012	biol	Amortization Of Discounts On Lines Of Credit AmortizationOfDiscountsOnLinesOfCredit	43000
CY2012	biol	Line Of Credit Facility Aggregate Commitment Fee Amount LineOfCreditFacilityAggregateCommitmentFeeAmount	240000
CY2012	biol	Decreased Receivables Pursuant To Two Thousand And Twelve Termination Agreement DecreasedReceivablesPursuantToTwoThousandAndTwelveTerminationAgreement	1100000
CY2012	biol	Payments Of Stock Repurchase Costs PaymentsOfStockRepurchaseCosts	235000
CY2012	biol	Percentage Of Sales Concentration To One Customer PercentageOfSalesConcentrationToOneCustomer	0.03	pure
CY2012	biol	Decreased Cost Of Revenues Pursuant To Two Thousand And Twelve Termination Agreement DecreasedCostOfRevenuesPursuantToTwoThousandAndTwelveTerminationAgreement	1100000
CY2012	biol	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue	1737000
CY2012	biol	Adjustments To Additional Paid In Capital Non Employee Equity Instruments AdjustmentsToAdditionalPaidInCapitalNonEmployeeEquityInstruments	23000
CY2012	biol	Sales To Customers Located Within United States SalesToCustomersLocatedWithinUnitedStates	0.71	pure
CY2012	biol	Derecognized Accounts Receivable Pursuant To Two Thousand And Twelve Termination Agreement DerecognizedAccountsReceivablePursuantToTwoThousandAndTwelveTerminationAgreement	155000
CY2012	biol	Sales To Customers Located Outside Of United States SalesToCustomersLocatedOutsideOfUnitedStates	0.29	pure
CY2012	biol	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Vested In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredVestedInPeriodIntrinsicValue
CY2012	biol	Share Based Compensation Arrangements By Share Based Payment Award Options Expired Vested Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredVestedWeightedAverageExercisePrice	4.84
CY2012	biol	Cost Of Revenue Prior To Nonrecurring Event CostOfRevenuePriorToNonrecurringEvent	32019000
CY2011Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.01	pure
CY2011Q2	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.01	pure
CY2012Q1	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2012-03-15
CY2012Q1	biol	Special Stock Dividends Declared SpecialStockDividendsDeclared	0.005	pure
CY2012Q2	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2012-06-08
CY2012Q2	biol	Special Stock Dividends Declared SpecialStockDividendsDeclared	0.005	pure
CY2011Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.01	pure
CY2012Q3	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2012-09-14
CY2012Q3	biol	Special Stock Dividends Declared SpecialStockDividendsDeclared	0.005	pure
CY2011Q4	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.01	pure
CY2012Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1900000
CY2012Q4	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2012-12-14
CY2012Q4	biol	Special Stock Dividends Declared SpecialStockDividendsDeclared	0.005	pure

Files In Submission

Name	View Source	Status
0001193125-13-110112-index-headers.html	Edgar Link	pending
0001193125-13-110112-index.html	Edgar Link	pending
0001193125-13-110112.txt	Edgar Link	pending
0001193125-13-110112-xbrl.zip	Edgar Link	pending
biol-20121231.xml	Edgar Link	completed
biol-20121231.xsd	Edgar Link	pending
biol-20121231_cal.xml	Edgar Link	unprocessable
biol-20121231_def.xml	Edgar Link	unprocessable
biol-20121231_lab.xml	Edgar Link	unprocessable
biol-20121231_pre.xml	Edgar Link	unprocessable
d447705d10k.htm	Edgar Link	pending
d447705dex211.htm	Edgar Link	pending
d447705dex231.htm	Edgar Link	pending
d447705dex311.htm	Edgar Link	pending
d447705dex312.htm	Edgar Link	pending
d447705dex321.htm	Edgar Link	pending
d447705dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g447705g41e68.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIOLQ
BIOLASE, INC Stock $biolq

2012 Q4 Form 10-K Financial Statement

#000119312513110112 Filed on March 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOLQ BIOLASE, INC Stock $biolq

2012 Q4 Form 10-K Financial Statement

#000119312513110112 Filed on March 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOLQ
BIOLASE, INC Stock $biolq